Poster presentation to demonstrate EBT-107’s potential to reduce clinically-relevant biomarkers and HBV DNA integration toward functional remission of chronic hepatitis B Oral presentation to ...
Excision reported positive safety and biodistribution data to 48 weeks in the first-in-human Phase 1/2 clinical evaluation of EBT-101 No serious adverse events or dose-limiting toxicities were seen in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback